States Take Sides in Stem Cell Debate

Report Read time:
States Take Sides in Stem Cell Debate

In the 10 years since University of Wisconsin scientists announced they had harvested potentially life-saving stem cells from human embryos, the bioethical dilemma presented by the science has stymied the federal government, split the GOP and has been debated in nearly every statehouse in the country.

Now, as the pace of new scientific discoveries in the field quickens, seven states —  California, Connecticut, Illinois, Maryland, New Jersey, New York and Wisconsin — are leading the world in financial and political support for stem-cell research, and Massachusetts is poised to join them .

Three — Iowa, Massachusetts and Missouri — have made the research legal, but not offered state funding, while six — Arkansas, Indiana, Louisiana, Michigan, North Dakota and South Dakota — have taken the path of most developed countries and restricted the studies.

President Bush and other opponents argue that stem-cell research that results in the destruction of human embryos is immoral. Scientists, patients and their advocates seek the freedom and resources to conduct this embryonic research they say could cure diseases that affect millions of Americans.
 
With powerful forces on both sides, Washington has remained stalled.

“The lack of federal leadership leaves a vacuum that states are trying to fill on a very piecemeal basis,” said Michigan state Rep. Andy Meisner (D), who has to tried to repeal his state's ban on the research for the past four years.
Bush said in his State of the Union Address Jan. 28 that groundbreaking new stem-cell research in which ordinary skin cells could replace the use of human embryos “has the potential to move us beyond the divisive debates of the past.”

But far from resolving the moral quandary, last November's highly publicized breakthrough has escalated the discussion.

Read the full report States Take Sides in Stem Cell Debate on Stateline.org's Web site.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up

MORE FROM PEW

About a dozen people stand examining large blue bins full of whole fish in a warehouse. Some people are in green clothes, others in blue, and all wear ballcaps. A few hold clipboards. Reducing Risk Strengthens the Seafood Supply Chain
A worker in a seafood market dumps bright orange shrimp from a blue bin onto a bed of ice between a lot of other seafood laid out for sale. Other workers are visible in the background, as are the arms of shoppers placing orders from the other side of the ice bed. Seafood Industry Benefits From Greater Vessel Transparency
An aerial view of a vast wetland, with scattered vegetation visible on sandy islands. In Western Australia, a Conservation Model for the World
A presentation being given by a businesswoman to a group of participants at a business conference. Four Plan Features Can Boost 'Retirement Readiness'
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics
Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.
Quick View
Pills illustration

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.